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Abstract
Background: Clostridium perfringens type C induced necrotizing enteritis (NE) causes high mortality in newborn
piglets. Immunization programs employing commercially available vaccines are used to prevent disease. Sows are
vaccinated during every gestation period and piglets take up antibodies from the colostrum. Antibodies against the
major clostridial toxin beta-toxin (CPB) are considered essential for protective immunity. Because the pathogen can
persist for several years on farms, continuous vaccination is essential to protect pig herds from the re-occurrence of NE.
Results: In two field trials using commercially available vaccines we monitored neutralizing anti-CPB antibodies in pigs
after vaccination. The first trial compared antibody titers in primiparous (gilts) and multiparous sows and their piglets
after vaccination. A proportion of gilts and their piglets’ showed no or low antibody titers. All multiparous sows
developed significantly higher serum and colostrum antibody titers after a booster vaccination shortly before
their next farrowing. These colostral antibody titer highly correlated with the serum antibody titer of their piglets
after consumption of colostrum. In a second field trial, we adapted the vaccination schemes using 3 instead of 2
initial vaccinations before the first farrowing of gilts. This significantly increased serum and colostrum antibody
titers in gilts and serum antibody titers in piglets.
Conclusion: We demonstrate that despite following recommended vaccination protocols, a proportion of gilts
might not sufficiently seroconvert to provide efficient passive immunity to their offsprings. A simple adaptation of
the vaccination scheme can however improve passive protection of piglets from NE.
Keywords: Clostridium perfringens type C, Beta-toxin, Neutralizing antibodies, Necrotizing enteritis, Porcine, Vaccination
Background
Clostridium perfringens type C causes necrotizing enteritis
(NE) in neonatal pigs and can lead to significant economic
losses on pig breeding farms [1]. Protection against NE is
achieved by vaccination of sows with commercially avail-
able type C toxoid vaccines [2, 3]. Because C. perfringens
type C can persist on farms over long periods, long-term
vaccination should remain despite the eradication of the
disease from once affected herds [4, 5]. If sufficient pro-
tective antibody levels in the sow colostrum are achieved,
piglets are passively protected by the uptake of antibodies
via the colostrum and milk of the sows [2]. The exact
amount and isotype of antibodies, which provide full pro-
tection to piglets under field conditions, are however not
known. C. perfringens beta-toxin (CPB), has been shown
to be the essential virulence factor for the pathogenesis of
NE [6–8]. It is likely, that antibodies neutralizing its effect
play a major role in protecting piglets from NE. The re-
sults of few studies on in pigs [3, 9–13] and laboratory
animal challenge models [2, 14] suggest that anti-CPB
antibodies are a useful indicator of immunity against C.
perfringens type C enteritis. This is supported by epi-
demiological data showing that vaccination largely reduces
the incidence of NE on pig breeding farms [2, 15, 16].
The applied vaccination scheme can influence the
levels of antibodies in sow colostrum and milk, and thus
protection against disease [12, 13]. Currently it is recom-
mended to vaccinate primiparous sows (gilts) twice after
insemination and before their first farrowing followed by
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one booster vaccination prior to every subsequent far-
rowing [2, 3, 13, 15]. Nevertheless, we and others have
experienced that NE occasionally still re-occurs in im-
munized herds [15, 17]. Failure of piglets to receive ad-
equate amounts of protective antibodies via colostrum
and milk, trypsin secretion deficiencies in piglets, and
colostral trypsin inhibitors are factors discussed to con-
tribute to such outbreaks [1].
In our current study, we evaluated the development of
neutralizing anti-CPB antibodies in serum and colos-
trum of vaccinated gilts and multiparous sows under
field conditions. In addition, we investigated serum neu-
tralizing anti-CPB antibody levels in piglets as an indica-
tor for the transfer of antibodies to the offspring of
vaccinated sows. We performed investigations on three
farms, which vaccinated against C. perfringens type C,
and one farm that served as negative control. According
to the results of this first investigation, we subsequently
evaluated an adapted vaccination scheme using two ini-
tial vaccine injections as basic immunization before
insemination and one booster immunization before the
first farrowing.
Results
First field investigation
The aim of our first field trial was to evaluate neutralizing
anti-CPB antibody titers as a measurement for protection
against NE under practical conditions on selected Swiss
breeding farms. We additionally compared antibody titers
of gilts with those of multiparous sows. The study was
conducted to evaluate regular vaccination practices used
on these farms and rather than to compare different vac-
cines, thus we grouped all vaccinated sows independent of
their origin (farm) and the vaccine used anticipating that
the source of vaccine has no effect.
On farms A-C, which continuously vaccinated against
C. perfringens type C enteritis (vaccination scheme
Fig. 1a, b), 4 out of the total 9 gilts, gained no neutraliz-
ing anti-CPB antibody titers in serum or colostrum sam-
ples. In 5 of 9 gilts serum antibody titers ranging from
4.77–9.54 IU (Fig. 1c) and colostrum antibody titers ran-
ging from 4.77–19.08 (Fig. 1d) were detected. Overall,
this resulted in median neutralizing anti-CPB antibody
titers of 0 IU/ml in serum and 4.77 IU/ml in colostrum
of gilts. Except for one sample (2.38 IU/ml), all milk
samples of gilts, taken two to three days after the far-
rowing, were negative for neutralizing anti-CPB anti-
bodies (Fig. 1d). In 6 of the piglets from gilts, no serum
antibody titers could be detected. The remaining 12 pig-
lets showed antibody titers ranging from 2.385–76.32 IU
(Fig. 1e). The median of the antibody titers of piglets of
gilts was 3.57 IU/ml. Multiparous sows showed signifi-
cantly higher serum antibody titers after the booster vac-
cination when compared to titers before the booster
vaccination and to those in gilts (Fig. 1c), ranging from
4.77–1221.12 IU with a median of 76.32 IU/ml. Colostral
antibody titers were detectable in every multiparous sow
and were also significantly higher than in gilts (range:
4.77–2442.24 IU/ml; median: 305.28 IU/ml; Fig. 1d). In
addition, neutralizing anti-CPB antibodies were detect-
able in 32 of 36 milk samples of multiparous sows, taken
two to three days after farrowing (range: 4.77–305.8 IU/ml;
median 19.08 IU/ml; Fig. 1d).
Antibody titers in serum of piglets from multiparous
sows ranged from 2.385–4884.48 IU/ml (median 76.32
IU/ml; Fig. 1e) and were significantly higher when com-
pared to piglets from gilts (p < 0.01, Fig. 1e). The colostral
antibody titers of multiparous sows strongly correlated with
the antibody titers of their piglets (Correlation coefficient:
0.79). Their association can be described with the following
regression model: Log (Y + 0.01) = 0.5614 + Log (X +
0.01)*0.5904, where Y is the antibody titer of the serum and
X the antibody titer of the colostrum (p-value < 0.01, R2 =
0.5608).
As a control, we included a non-vaccinating farm
which did not experience NE over more than 3 years
prior to the start of the study. In all serum and colos-
trum samples from this farm, we were unable to detect
neutralizing antibodies against CPB.
Second field investigation using an adapted vaccination
scheme
In the first part of our study, we detected relatively low
or even no titers of neutralizing anti-CPB antibodies in
gilts and their piglets despite following the manufacturers
recommended vaccination scheme. We next wanted to test
whether an adapted vaccination scheme, using three instead
of two initial vaccine injections for gilts leads to increased
neutralizing anti-CPB antibody titers (Fig. 2). For this pur-
pose, we purchased and used the two C. perfringens type C
vaccines, which were licensed and commercially available at
that time in Switzerland. Both contain inactivated C. per-
fringens type C culture supernatants. Gilts in the control
groups (group 1.1 and 2.1) were vaccinated following the
manufacturer recommendation against C. perfringens type
C, which included two injections of the vaccine ante-par-
tum (a.p.). Gilts in the groups with the adapted vaccination
scheme (group 1.2 and 2.2) were vaccinated two times prior
to insemination and received an additional booster vaccin-
ation prior to farrowing.
Prior to vaccination, no neutralizing anti-CPB anti-
bodies were detected in any of the four groups of gilts.
In Group 1.1 (Fig. 2a, standard vaccination scheme, vac-
cine 1) no serum antibodies were detected before and
after the first vaccination (Fig. 3a). After the second vac-
cination, at time of farrowing, 3 out of 13 sows did not
gain detectable serum neutralizing anti-CPB antibody
titers, the other 10 sows showed antibody titers ranging
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from 1.19–2.38 IU/ml. The overall median antibody titer
in this group was 1.19 IU/ml. (Fig. 3a). All sows had de-
tectable colostrum antibody titers ranging from 1.19–
9.54 IU/ml, with a median of 2.39 IU/ml. Three out of
26 piglets did not gain detectable serum antibody titers,
the other 23 gained serum antibodies ranging from
Fig. 1 Comparison of neutralizing anti-CPB antibody titers in gilts and multiparous sows and their piglets. a & b: Immunization and sampling
schedule for field trial. c, d & e: Neutralizing anti-CPB antibodies in gilts, multiparous sows and piglets on farms vaccinating against C. perfringens
type C. a. Timeline of sample collection in the first field trial for gilts: T1: before the second vaccination, T2 and Col: in the first 24 h postpartum
(p.p.), M, P: 2 days p.p.; T: blood sample of the sow, Col: colostrum, M: milk, P: blood samples of piglets. b. Timeline of sample collection in the first
field trial for multiparous sows: T1: before the booster vaccination, T2 and Col: in the first 24 h p.p., M, P: 2 days p.p.; T: blood sample of the sow,
Col: colostrum, M: milk, P: blood samples of piglets. c. Neutralizing anti-CPB antibody titers (logarithmic scale) in serum of gilts and multiparous
sows. Serum from gilts was taken before (T1) and after the second vaccination (T2), serum of multiparous sows before (T1) and after the booster
vaccination (T2) of subsequent farrowings. Box plots depicting median, quartiles and range. Antibody titers in gilts at T2 ranged from 0 to 9.54 IU/ml
with a median of 0 IU/ml, whereas titers in sows were significantly higher (p < 0.01 for all time points). ANOVA, Tukey-Kramer Multiple-Comparison
Test. d. Neutralizing anti-CPB antibody titers in colostrum (Col) and milk (M) samples of gilts and multiparous sows. Colostral and milk antibody titers of
multiparous sows were significantly higher than antibody titers of gilts (*p< 0.01 for all time points and groups). ANOVA, Tukey-Kramer Multiple-
Comparison Test. e. Neutralizing anti-CPB antibody titers in serum of piglets from gilts (0) and multiparous sows (1). Antibody titers from piglets of
multiparous sows were significantly higher than antibody titers from piglets of gilts (*p < 0.01). ANOVA, Tukey-Kramer Multiple-Comparison Test
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1.19–19.08 IU/ml. The overall median antibody titer in
this group of piglets was 2.39 IU/ml (Fig. 3c).
In Group 1.2 (Fig. 2b, adapted vaccination scheme,
vaccine 1), 4 and 5months after the basic immunization
5 of 12 gilts did not gain detectable serum antibody
titers, whereas 7 gilts gained antibody titers ranging
from 1.19–4.77 IU/ml. This resulted in a median serum
antibody titer of 1.19 IU/ml (Fig. 3a). At time of farrow-
ing after the booster vaccination, all gilts had detectable
serum and colostrum antibody titers (range serum:
1.19–38.16 IU/ml, median: 9.54 IU/ml; range colostrum:
2.38–152.64 IU/ml, median colostrum: 19.08 IU/ml)
(Fig. 3a, b). The median antibody titer in the colos-
trum of gilts was thus approximately 8x higher com-
pared to group 1.1 (p-value: < 0.01). All piglets gained
detectable serum antibody titers (range: 1.19–152.64
IU/ml, median: 19.08 IU/ml). Compared to the piglets
from group 1.1 the median antibody titer was 7.9x
times higher in the group with the adapted vaccin-
ation scheme (Group 1.2; p-value: < 0.01) (Fig. 3c).
In Group 2.1 (Fig. 2c, standard vaccination scheme,
vaccine 2) no serum antibodies were detected in gilts be-
fore and after the first vaccination. At time of farrowing
9 out of 16 sows did not gain a detectable serum anti-
body titer, the other 7 sows did gain antibody titers ran-
ging from 1.19–2.38 IU/ml (Fig. 3a). The overall median
antibody titer was 0 IU/ml. All sows gained detectable
colostrum antibody titers (range: 1.19–19.08 IU/ml, me-
dian: 1.19 IU/ml) (Fig. 3b). Nine out of 31 piglets did not
gain any detectable serum antibody titer, the other 22
gained serum antibody titers ranging from 1.19–4.77,
resulting in a median of 1.19 IU/ml (Fig. 3c).
In group 2.2 (Fig. 2d, adapted vaccination scheme, vac-
cine 2) two of 12 sows gained antibody titers measured
4 months after the basic immunization (1.19 IU/ml, 2.38
IU/ml respectively). At time of farrowing, after the
booster vaccination, 3 of 12 sows did not gain a detect-
able serum antibody titer, the other 9 did gain a serum
antibody titer ranging from 1.19–2.38 IU/ml (Fig. 3a).
The overall median antibody titer value was 1.19 IU/ml.
Fig. 2 Immunization and sampling schedule for second field trial. a. Standard vaccination scheme (2 applications), Porcilis® ColiClos ad us. vet.
(Group 1.1). b. Adapted vaccination scheme (3 applications), Porcilis® ColiClos ad us. vet. (Group 1.2). c. Standard vaccination scheme (2
applications), Suisen ad us. vet. (Group 2.1). d. Adapted vaccination scheme (3 applications), Suisen ad us. vet. (Group 2.2). Timeline of sample
collection in the vaccination trial; T0: before vaccination, 3 or 4 weeks ante insemination (a. i.), T1: 5 or 6 weeks ante-partum, T2: 2 or 3 weeks ante-
partum, T3: at farrowing, P: 2 to 3 days postpartum (p.p.); T: blood sample of the sow, Col: colostrum, P: blood samples of piglets, NaCl injections
were performed to achieve even numbers of injections between all groups
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All sows gained detectable colostral antibody titers
(range1.19–38.16 IU/ml, median: 4.77 IU/ml) (Fig. 3b).
Compared to group 2.1 the median colostrum antibody
titer was 4x times higher in group 2.2, but this result
was statistically insignificant (p-value: > 0.05). One piglet
of 26 did not gain a detectable serum antibody titer, the
other 25 piglets gained antibody titers ranging from
1.19–19.08 IU/ml, resulting in a median antibody titer of
1.79 IU/ml (Fig. 3c). Thus, serum antibody titers of
group 2.2 were approximately 1.5 x higher than those of
group 2.1 and this difference was statistically significant
(p-value: < 0.05).
Fig. 3 Neutralizing anti-CPB antibody titers in gilts and their piglets using an adapted vaccination scheme. Group 1.1: standard vaccination
scheme vaccine 1; Group 1.2: adapted vaccination scheme vaccine 1; Group 2.1: standard vaccination scheme vaccine 2; Group 2.2: standard
vaccination scheme vaccine 2. a. Antibody titers in serum samples of gilts. Serum antibody titers of gilts at time of farrowing (T3) from groups
with adapted vaccination scheme (1.2 and 2.2) were significantly higher compared to the standard scheme using the identical vaccine (1.1 and
2.1). (* = p < 0.05; ** = p < 0.01). ANOVA, Tukey-Kramer Multiple-Comparison Test. b. Antibody titers in colostrum samples of gilts. Colostral
antibody titers of gilts from group 1.2 with the adapted vaccination scheme were significantly higher compared to the standard scheme using
the identical vaccine (1.1) (** = p < 0.01). The elevation of antibody titers in group 2.2 was statistically non-significant compared to group 2.1.
There was no statistical significance between group 2.1 and 2. ANOVA, Tukey-Kramer Multiple-Comparison Test. c. Antibody titers in serum
samples of piglets. Serum antibody titers of piglets from groups with the adapted vaccination scheme (1.2 and 2.2) were significantly higher
compared to the standard scheme using the identical vaccine (1.1 and 2.1). (* = p < 0.05; ** = p < 0.01) ANOVA, Tukey-Kramer Multiple-Comparison Test
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Discussion
The first aim of our study was to evaluate the levels of
neutralizing anti-CPB antibody titers induced by routine
vaccination against C. perfringens type C enteritis in
sows and their piglets under practical condition in Swiss
pig breeding farms. As CPB is the essential toxin se-
creted by C. perfringens type C strains [6], such antibody
titers are a useful indicator for passive immunity against
NE, as they correlate with protection against the effects
of C. perfringens type C supernatants in lethal challenge
models in pigs [9]. Our results clearly show that differ-
ent commercially available vaccines effectively induce
development of antibodies capable of neutralizing CPB
in vaccinated sows. We could clearly demonstrate that
booster vaccinations before every farrowing leads to the
development of high colostrum and even milk antibody
titers in multiparous sows and that these antibodies were
transferred to their offspring. As our study was primarily
designed to determine CPB neutralizing activity we did
not determine the Ig class of these antibodies. However,
taking studies about IgA and IgG in colostrum and milk
of sows into account [18, 19], it can be anticipated that
colostrum derived antibodies belonging to the class of
IgG are crucially important for the development of im-
munity against NE in piglets. It seems likely that also
lactogenic transferred IgA adds to a passive mucosal im-
munity against CPB and potentially other clostridial
toxins, but the contribution of colostral versus lacto-
genic immunity would still have to be investigated in
more detail using different experimental setups. The
absence of neutralizing antibodies in milk from gilts ob-
served in our first field trial however is a further indica-
tion for a lower passive immunity and thus elevated
susceptibility of piglets from gilts towards development
of NE.
Studies evaluating the minimal antibody titer, which
confers protective immunity in piglets against NE under
field condition, are lacking, thus it is not possible to
scientifically demonstrate protection against NE in our
study. According to Hogh [3] titers of 10 IU/ml of beta-
antitoxin in colostral whey should be considered as suffi-
cient for protecting piglets against NE. These titers were
however determined differently from our method and do
not necessarily reflect antibodies against CPB only.
Nevertheless, neutralizing anti-CPB antibody titers of 10
IU/ml and higher were readily reached in multiparous
sows after booster immunizations, suggesting that the
applied vaccination scheme was sufficient to induce pro-
tective immunity in their piglets.
Interestingly, similar to our previous results using
samples of a vaccine efficacy trial [9], also under field
conditions, gilts frequently developed low colostrum
antibody titers, which resulted in much lower antibody
titers in their piglets compared to multiparous sows,
which were continuously boostered during every gesta-
tion. Individual piglets even showed no detectable neu-
tralizing anti-CPB serum antibody titers. Very early
studies in the 60ies and 70ies showed that oral and also
s.c. administration of beta-antitoxin leads to detectable
titers of antibodies in piglet serum and actually leads to
partial protection of piglets against NE [3, 16]. Applica-
tion of antiserum to piglets was even suggested as an
alternative option to vaccination of sows to reduce the
incidence of NE by these authors at that time. Currently
it is still unknown, which antibodies transferred from
the colostrum to the piglets prevent NE and how exactly
such antibodies interfere with the pathogenesis of NE.
The pathogenesis of NE involves an initial overgrowth of
C. perfringens type C, secretion of multiple toxins in-
cluding targeted effects of CPB, mainly on endothelial
cells in the small intestinal mucosa [1, 7, 20] (Posthaus
et al. submitted to JVDI). It is likely that IgA antibodies
against several clostridial virulence factors, amongst
them CPB, taken up with colostrum and milk have a
direct protective effect in the intestinal lumen. Due to
the high susceptibility of endothelial cells to CPB, circu-
lating neutralizing IgG antibodies against CPB might
also be important in preventing the development of the
necro-hemorrhagic lesions observed in NE. Our results,
which focus on the levels of anti-CPB antibodies that
neutralize the toxic effects of this essential virulence
factor of C. perfringens type C, thus suggest that piglets
from gilts are at higher risk to develop disease once they
ingest C. perfringens type C shortly after birth. This
might explain our observation that in outbreaks of NE
on pig breeding farms, which vaccinate against C. per-
fringens type C, mainly piglets from gilts, succumb to
disease (Nathues, personal observation).
In the second part of our study, we demonstrated that
an adaptation of the vaccination scheme using three in-
stead of two vaccine injections for the basic immunization
of gilts leads to a marked and significant increase in anti-
body levels in colostrum and piglets, respectively. This re-
sult was independent of the vaccine used. Thus in cases
where needed, this very simple adaptation can be used to
increase the level of immunity in the most vulnerable sub-
group of the pig population. We detected differences in
antibody titers induced by two different commercially
available vaccines. However, it was beyond the scope of
our study to compare different products, which would re-
quire much larger cohorts of animals and groups to be
tested.
It should be noted that under practical conditions it
seems to be generally sufficient to use a two-injection
basic immunization protocol for gilts. This has to be
followed by strict enforcement of one booster vaccin-
ation during every subsequent pregnancy of each sow.
This will ensure that individual differences in antibody
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response upon basic vaccination of gilts, as observed in
our study, will be raised to similar levels during subse-
quent booster vaccinations. Thus all multiparous sows
can be expected to transfer protective antibody levels to
their offsprings. Once established, this vaccination pro-
gram is known to prevent outbreaks of NE in most
cases. Combined with good sanitation management, it
should keep the environmental contamination with C.
perfringens type C on the farm low, as newborn piglets
should not shed the pathogen in large amounts [5]. Under
regular farm management practices in Switzerland, gilts
usually represent a maximum of 15–25% of all sows in a
breeding farm. Because the infectious pressure and the
population of piglets at risk (piglets from gilts) will both
be low in properly vaccinated herds, the risk of re-
occurrence of the disease can also be considered as low.
Nevertheless, under circumstances where the infectious
pressure for newborn piglets is high or the population of
non-immune and thus highly susceptible piglets is large,
immunity of piglets from gilts can easily be increased to
achieve a higher level of protection against NE. Examples
of such circumstances include cases of acute outbreaks of
NE in previously non-vaccinated herds, a management
which includes high stocking rates with gilts, or cases of
herds, which experience recurrent outbreaks of NE des-
pite vaccination programs.
Conclusion
We show that currently recommended C. perfringens
type C vaccination programs induce good levels of anti-
bodies that neutralize the essential virulence factor of C.
perfringens type C in colostrum and milk as well as pig-
let serum of multiparous sows. The standard vaccination
scheme however might leave a proportion of piglets
from gilts susceptible to disease. In cases of recurrent
problems, where the immune protection of this subpop-
ulation of piglets in a herd has to be improved, a simple
extension of the vaccination scheme for gilts including a
basic immunization before insemination and a booster
immunization before the first farrowing can be applied
to increase neutralizing anti-CPB antibody levels and
thus most likely reduce the risk of outbreaks of NE in
pig breeding farms.
Material and methods
Animal experiments were limited to intramuscular (i.m.)
injections of licensed and commercially available vaccines
or sterile NaCl, blood and colostrum sampling of sows
and piglets. They were approved by the Bernese Cantonal
Veterinary Office (Animal Experiment No. BE61/16).
First field trial
Four farms participated in this trial. Three farms had
established a continuous vaccination program against C.
perfringens type C for a minimum of two years. Two
farms vaccinated their sows using Porcilis® ColiClos ad
us. vet. (MSD Animal Health GmbH; farm A and B) and
one farm vaccinated their sows using Clostricol ad us.
vet. (Provet AG; farm C). Farm A and B vaccinated their
gilts 7 and 3 weeks prior to farrowing and their multip-
arous sows 3 weeks prior to every consecutive farrowing.
Farm C vaccinated their gilts 5 and 2 weeks prior to far-
rowing and their multiparous sows 2 weeks prior to
every consecutive farrowing. The fourth farm served as a
control farm, which did not vaccinate their sows against
C. perfringens type C (farm D).
All participating farms had confirmed absence of clin-
ical and pathological signs of NE for a minimum period
of one year prior to the study. On the vaccinating farms,
blood and colostrum samples of 9 gilts, 36 multiparous
sows (in their 2nd to 9th pregnancy) and 2 piglets per
litter were collected. On the non-vaccinating farm, blood
and colostrum samples of 2 gilts and 14 multiparous
sows as well as 2 piglets per litter were collected. Blood
samples were collected 3 weeks before the expected date
of delivery (before second immunization in gilts and
booster immunization in multiparous sows; T1) as well
as in the first 24 h postpartum (p.p.) (T2). Colostrum
(Col) and milk (M) samples were collected within 24 h
(Col) and 2 to 3 days p.p. (M). Sera from two piglets per
litter were collected 2 days p.p. (P).
Second field trial
The farm with the highest production rate and the most
compliant management (farm C) was chosen to test an
adapted vaccination scheme using the two commercially
available vaccine against C. perfringens type C in
Switzerland at the time of the start of this trial (October
2017). Sixty-one 6months old sows were randomly
assigned to three groups of 15 and one group of 16 sows
respectively. Eight sows developed health issues independ-
ent of the vaccination and were excluded from the study.
Group 1.1 and 1.2 were vaccinated using vaccine 1:
Porcilis® ColiClos ad us. vet. Vaccine (MSD Animal
Health GmbH, Lucerne, Switzerland). Group 1.1 was
vaccinated following the manufacturer recommendation
against C. perfringens type C, which included two injec-
tions of 2 ml of the vaccine i.m. 6 (T1) and 2 (T2) weeks
ante-partum (a.p.). Group 1.2 was vaccinated three times
prior to the first farrowing. They received 2 ml of the
vaccine i.m. 4 weeks prior to insemination (T0) and at
the day of insemination (basic immunization). They
received an additional booster vaccination with 2 ml of
the vaccine 2 weeks before farrowing. To exclude effects
related to the different injection schedules sows in one
group received i.m. NaCl injections of 2 ml at those time
point when sows from the other groups received their
vaccination.
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Thus, in addition, gilts from group 1.1 received i.m. in-
jections of 2 ml NaCl 4 weeks prior to insemination (T0)
and at the day of insemination. Group 1.2 received i.m.
injections of 2 ml NaCl 6 weeks ante-partum (T1).
Group 2.1 and 2.2 were vaccinated using vaccine 2:
Suisen ad us. vet. Vaccine (Dr. E. Graeub AG, Bern,
Switzerland). Again, group 2.1 was vaccinated according
to the manufacturer recommendations, twice before the
first farrowing. They received 2 ml of the vaccine i.m. 6
(T1) and 3 (T2) weeks a.p.. In addition, they received
i.m. injections of 2 ml NaCl 3 weeks prior to insemination
(T0) and at day of insemination. Group 2.2 was vaccinated
three times prior to the first farrowing. They received 2ml
of the vaccine i.m. 3 weeks prior to insemination (T0) and
at day of insemination (basic immunization). They re-
ceived an additional booster vaccination with 2ml of the
vaccine 3 weeks before farrowing. Group 2.2 received i.m.
injections of 2 ml NaCl 6 weeks ante-partum (T1).
Blood samples from all gilts were collected prior to in-
semination (T0), at day of insemination and twice before
farrowing (T1 and T2). Colostrum and blood from sows
were collected in the first 24 h p.p. (Col and T3). Two to
three days p.p. blood was drawn from two piglets per
litter (P). Serum and skimmed milk were generated by
centrifugation of blood samples (3,500 x g, 10 min) and
colostrum (23,000 x g, 20 min). The samples were stored
in aliquots at − 20 °C until examination.
Determination of neutralizing anti-CPB antibody titers
The cell culture essay using primary porcine aortic
endothelial cells (PAEC) was performed as recently de-
scribed [9]. Briefly, purified recombinant CPB was pre-
incubated with serum and colostrum samples of sows
and piglets for 1 h at room temperature and then added
to PAEC grown in 96-wells at a concentration of 100 ng
toxin/ml medium. Cells were incubated at 37 °C for 24 h
and subsequently cell vitality was measured using light
microscopy and a cell titer blue assay (CellTiter-Blue®
Cell Viability Assay, Promega Corporation, Madison,
USA). The World Health Organization International
Standard Serum of equine origin (antibody titer 4770
IU/mL, National Institute for Biological Standards and
Control, Potters Bar, Hertfordshire, EN6 3QG, UK) was
used as a positive control and as reference for antibody
titer values. Serum derived from non-vaccinated pigs
was used as a negative control.
Statistics
Statistics were performed using the NCSS software
(Nashville, USA, http://www.ncss.com). Shapiro–Wilk
test was applied to test normality. The logarithm trans-
formation (log(y + 0.01)) was used, as the antibody titers
were not normally distributed. The differences in anti-
body titers between the treatment groups were evaluated
by means of a repeated measures analysis of variance,
using the animal identification number as a subject vari-
able. The post hoc test applied for multiple comparisons
was the Tukey–Kramer Multiple-Comparison Test. The
level of significance was defined as 0.05 and 0.01 re-
spectively. The associations between the antibody titers
in serum and colostrum was calculated by means of lin-
ear regression of the log transformed variables and
Spearman-Rank correlation coefficients.
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